about
Screening instruments for substance use and brief interventions targeting adolescents in primary care: a literature reviewPerceived cannabis use norms and cannabis use among adolescents in the United StatesE-cigarette prevalence and correlates of use among adolescents versus adults: a review and comparisonAssociations between cigarette smoking and pain among veteransSubstance abuse and rehabilitation: responding to the global burden of diseases attributable to substance abuse.Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use Screening in Primary Care PatientsSubstance use and mental diagnoses among adults with and without type 2 diabetes: Results from electronic health records dataUsing electronic health record data for substance use Screening, Brief Intervention, and Referral to Treatment among adults with type 2 diabetes: Design of a National Drug Abuse Treatment Clinical Trials Network study.Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.An item response theory analysis of DSM-IV criteria for hallucinogen abuse and dependence in adolescents.Using a latent variable approach to inform gender and racial/ethnic differences in cocaine dependence: a National Drug Abuse Treatment Clinical Trials Network study.Suicidal ideation and substance use among adolescents and young adults: a bidirectional relation?Use of substance abuse services by young uninsured american adults.Private health insurance coverage for substance abuse and mental health services, 1995 to 1998Alcohol dependence and use of treatment services among women in the community.Inhalant abuse and dependence among adolescents in the United States.Psychostimulant dependence in a community sample.Injection drug use among stimulant users in a national sampleUse of alcohol treatment and mental health services among adolescents with alcohol use disordersUsing electronic health records data to assess comorbidities of substance use and psychiatric diagnoses and treatment settings among adults.Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trialNonmedical stimulant use among young Asian-Americans, Native Hawaiians/Pacific Islanders, and mixed-race individuals aged 12-34 years in the United StatesSubstance use disorders and co-morbidities among Asian Americans and Native Hawaiians/Pacific IslandersConstruct and differential item functioning in the assessment of prescription opioid use disorders among American adolescents.How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions.Problem drinking and low-dose naltrexone-assisted opioid detoxification.Abuse and dependence on prescription opioids in adults: a mixture categorical and dimensional approach to diagnostic classification.Reduced cannabis use after low-dose naltrexone addition to opioid detoxificationRecent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusersGender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network.The prevalence and clinical significance of inhalant withdrawal symptoms among a national sampleInhalant use and disorders among adults in the United States.Pharmacological enhancement of naltrexone treatment for opioid dependence: a reviewThe epidemiology of alcohol use disorders and subthreshold dependence in a middle-aged and elderly community sampleCo-occurring amphetamine use and associated medical and psychiatric comorbidity among opioid-dependent adults: results from the Clinical Trials Network.Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network.Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence.Substance use disorders and comorbid Axis I and II psychiatric disorders among young psychiatric patients: findings from a large electronic health records database.Sexual risk behaviors and HIV risk among Americans aged 50 years or older: a reviewSmoking cessation interventions for adults aged 50 or older: A systematic review and meta-analysis.
P50
Q27022396-7F9AEA43-47BB-4D36-87CB-CC26B359F8E2Q27309105-1ADD8757-1D57-4F96-A91A-CA8965FB7415Q28237014-DB7B417E-A8D2-4865-93CD-D0C8207A8990Q28387756-8204F6AC-7730-40E4-8D55-581A96004386Q30485064-EE853FE1-E372-4C16-AF65-7E29C2023F06Q30837457-2178CE7C-159B-4D0F-8806-C66326B4BCCEQ30995447-D3C37D08-F704-4CA4-9314-380747AF8E27Q31022565-62AEFA1D-70DA-40F8-B672-EC03152C9EB7Q33595868-B535CC4D-89BB-43F9-82B0-F67A9FE70E95Q33624766-CB4FBA32-07D4-4E35-B526-BBFE338B55DBQ33750900-3D5752EE-7334-4A6C-A2EE-AE062D38F24FQ34031665-D8A04D15-40B2-42B7-8822-8439CD32D698Q34131518-5A54B0AE-6F75-4113-AE49-7EDAFAC93D07Q34131524-96CD5C7F-9671-4808-AD72-2194B05BE809Q34131534-D3786063-851A-453C-AE2D-DE4B84F0A7EFQ34131540-861B7E10-6AB1-479F-9235-69E64500A708Q34163070-9ED67758-B173-4AA4-B477-8935B1B721F1Q34195746-D1841E2D-E946-4ED8-945F-E06C44F07FDCQ34338332-83AADAB4-7A63-47C1-8CBA-C996EF433820Q34556368-C59D30A8-1916-49E7-89C8-EF48D7F22E67Q34595756-D0288CB1-989C-4EE7-99E3-AF7F33E40FCCQ34620189-57BBDE31-D7F4-41EE-8087-DBCB1277F522Q34747302-3B6817BC-6E84-4D8B-BCEF-49EA07B6A3B6Q34788333-285CE68C-FCD5-4DAE-948B-B722BD94CECAQ34854778-928ACB22-616C-452E-96ED-46799ED79C79Q34884212-1B7FF88C-7310-4069-84E2-A5C9CEB2DE87Q34912225-45A70528-EA0D-4E2E-94E4-32588CF96D49Q34963907-4D84B7BB-F8DE-42E2-BE39-1A3C797CA190Q35065030-231BCB3A-56D2-48AE-ACEE-DD1B8993F58DQ35065975-95E2E40B-3C81-4747-ADB8-B5072E0664ECQ35068682-E945523B-0627-4494-B96C-F50094C70A20Q35069802-63C7C575-4258-48AA-B7CA-415F791E14BFQ35084340-14CE6444-A35C-4EE7-9D18-369B35493738Q35130501-FAE249C3-B90E-43F2-8935-7C9AA89C240CQ35185527-E935BCA8-130E-421F-907F-33AE18D01C93Q35206845-DAFBDAF3-0C3D-440A-9A7A-15169254551FQ35228546-7317581F-1B37-4CF4-8760-1B735627606AQ35380871-9028FB19-1A22-44DB-9F5B-8697D0D8CAF2Q35541920-57D0B9CD-25E8-4B89-9896-D2D8DDD6A076Q35669664-09098B5A-B5CF-4E71-91A8-934842E56F53
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Li-Tzy Wu
@ast
Li-Tzy Wu
@en
Li-Tzy Wu
@es
Li-Tzy Wu
@nl
Li-Tzy Wu
@sl
type
label
Li-Tzy Wu
@ast
Li-Tzy Wu
@en
Li-Tzy Wu
@es
Li-Tzy Wu
@nl
Li-Tzy Wu
@sl
altLabel
Litzy Wu LT Wu, L-T Wu
@en
prefLabel
Li-Tzy Wu
@ast
Li-Tzy Wu
@en
Li-Tzy Wu
@es
Li-Tzy Wu
@nl
Li-Tzy Wu
@sl
P108
P106
P1153
7404903026
P31
P496
0000-0002-5909-2259